Skip to main content
Phalguni Deswal on Muck Rack

Phalguni Deswal

Verified
India
As seen in: Drug and Device World, MSN, Yahoo Finance, GlobalData, Army Technology, Pharmaceutical-Technology.com, Yahoo Finanzas, Clinical Trials Arena, Citeline, Medtech Insight, Scrip and
Health Editor at Drug and Device World Contact me at editor@druganddeviceworld.com
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Phalguni

Contact Phalguni, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Tariffs Meant To Reshore Medtech Would Send It Offshore, Industry Tells USTR

|
By Phalguni Deswal Verified
| Medtech Insight Verified
Medtech manufacturers, hospitals and EU trade bodies are pressing USTR to exempt medical devices from proposed Section 301 forced-labor tariffs, warning the levies would raise healthcare costs, disrupt fragile supply chains, and push production offshore rather than reshore it. Under the proposed framework, 46 economies would face a 12.5% tariff rate, while 14 economies viewed as having relatively stronger forced-labor import prohibition regimes would be subject to a 10% rate.
Open in Who Shared Issue with article?

Roche Turns To Industrial Robotics Partner ABB Robotics In Lab Automation Push

|
By Phalguni Deswal Verified
| Citeline Verified
Roche and ABB Robotics are jointly developing AI-powered robotic systems for pathology and central laboratories, targeting workflow bottlenecks driven by labor shortages and precision medicine demand. By combining robotics hardware with diagnostic process knowledge, the companies aim to create integrated workflows rather than isolated automation components.
Open in Who Shared Issue with article?

ResMed Sells MatrixCare Software Business For $490m In Portfolio Overhaul

|
By Phalguni Deswal Verified
| Citeline Verified
The eight-year post-acute care software venture is sold to Frazier Healthcare Partners at a notable discount from its 2018 acquisition price as the medtech leader pivots toward its 2030 growth strategy. Based on preliminary fiscal 2026 results, MatrixCare represented approximately $220m of revenue and about $55m of non-GAAP operating profit.
Open in Who Shared Issue with article?
See all 1,885 articles